92.89MMarket Cap
LossP/E TTM
Key Figures
1.620Open
1.630High
576.81KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.96%Turnover Ratio
1.600Prev. Close
1.520Low
631.56KTurnover
LossP/E Static
2.20P/B
0.00%Div Yield TTM
-34.28%ROA
6.17552wk High
0.72Volume Ratio
-55.85MNet Profit
60.32MShares
-0.4550EPS TTM
1.18Beta
-51.76%ROE
1.07052wk Low
6.88%Amplitude
--Gross Margin
92.89MMarket Cap
-5.36Reward/Risk
5.57%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Aldeyra Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 110 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.80.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Aldeyra Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Aldeyra Therapeutics Inc Highlights
StrengthsRisks
Aldeyra Therapeutics Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Aldeyra Therapeutics Inc
ALDX
6
Ionis Pharmaceuticals Inc
IONS
26
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Aldeyra Therapeutics Inc Info
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
Ticker SymbolALDX
CompanyAldeyra Therapeutics Inc
CEOBrady (Todd C)
Websitehttps://www.aldeyra.com/
Shareholders
FAQs
What is the current price of Aldeyra Therapeutics Inc (ALDX)?
The current price of Aldeyra Therapeutics Inc (ALDX) is 1.54.
What is the symbol of Aldeyra Therapeutics Inc?
The ticker symbol of Aldeyra Therapeutics Inc is ALDX.
What is the 52-week high of Aldeyra Therapeutics Inc?
The 52-week high of Aldeyra Therapeutics Inc is 6.17.
What is the 52-week low of Aldeyra Therapeutics Inc?
The 52-week low of Aldeyra Therapeutics Inc is 1.07.
What is the market capitalization of Aldeyra Therapeutics Inc?
The market capitalization of Aldeyra Therapeutics Inc is 92.89M.
Is Aldeyra Therapeutics Inc (ALDX) currently rated as Buy, Hold, or Sell?
According to analysts, Aldeyra Therapeutics Inc (ALDX) has an overall rating of Buy, with a price target of 6.80.
What is the Earnings Per Share (EPS TTM) of Aldeyra Therapeutics Inc (ALDX)?
The Earnings Per Share (EPS TTM) of Aldeyra Therapeutics Inc (ALDX) is -0.56.
